# A Clinical Study to Explore the Safety and Efficacy of CT1390B in Relapsed/ Refractory Acute Myeloid Leukemia

> **NCT07441980** · PHASE1 · NOT_YET_RECRUITING · sponsor: **Institute of Hematology & Blood Diseases Hospital, China** · enrollment: 18 (estimated)

## Conditions studied

- Relapsed/Refractory Acute Myeloid Leukemia(AML)

## Interventions

- **DRUG:** CAR-T cells chimeric antigen receptor T cells

## Key facts

- **NCT ID:** NCT07441980
- **Lead sponsor:** Institute of Hematology & Blood Diseases Hospital, China
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-03-02
- **Primary completion:** 2026-12-31
- **Final completion:** 2028-06-30
- **Target enrollment:** 18 (ESTIMATED)
- **Last updated:** 2026-03-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07441980

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07441980, "A Clinical Study to Explore the Safety and Efficacy of CT1390B in Relapsed/ Refractory Acute Myeloid Leukemia". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT07441980. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*